+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pancreatitis - Pipeline Review, H2 2019

  • ID: 4866551
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 96 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • BioNTech SE
  • Cypralis Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mallinckrodt Plc
  • MORE
Pancreatitis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2019, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 1, 17, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • BioNTech SE
  • Cypralis Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Mallinckrodt Plc
  • MORE
Introduction
Report Coverage
Pancreatitis - Overview
Pancreatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pancreatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pancreatitis - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Bessor Pharma LLC
Bharat Serums And Vaccines Ltd
BioNTech SE
CalciMedica Inc
Centeer BioTherapeutics Ltd Co
Cypralis Ltd
D&D Pharmatech Co Ltd
DiaMedica Therapeutics Inc
General Regeneratives Shanghai Ltd
Generon (Shanghai) Corp Ltd
GlaxoSmithKline Plc
GNT Pharma Co Ltd
Johnson & Johnson
LipimetiX Development Inc
Mallinckrodt Plc
Novartis AG
PNB Vesper Life Science Pvt Ltd
SCM lifescience Co Ltd
Shenzhen HighTide Biopharmaceutical Ltd
SN BioScience
Sun BioPharma Inc
Takeda Pharmaceutical Co Ltd
Pancreatitis - Drug Profiles
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEM-2814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-1430E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-1440G - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-4066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-4620 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DM-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GR-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-180 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2795039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-428 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-6288B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTD-4010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-3964 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVT-5873 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pancrelipase DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNB-081 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Agonize renalase for Acute Kidney Injury, Acute Pancreatitis and Cisplatin Induced Kidney Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCM-AP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclophilin for Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KMO for Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-671 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLY-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulinastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Withaferin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pancreatitis - Dormant Projects
Pancreatitis - Discontinued Products
Pancreatitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Pancreatitis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Pancreatitis - Pipeline by Angion Biomedica Corp, H2 2019
Table 13: Pancreatitis - Pipeline by Bessor Pharma LLC, H2 2019
Table 14: Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H2 2019
Table 15: Pancreatitis - Pipeline by BioNTech SE, H2 2019
Table 16: Pancreatitis - Pipeline by CalciMedica Inc, H2 2019
Table 17: Pancreatitis - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2019
Table 18: Pancreatitis - Pipeline by Cypralis Ltd, H2 2019
Table 19: Pancreatitis - Pipeline by D&D Pharmatech Co Ltd, H2 2019
Table 20: Pancreatitis - Pipeline by DiaMedica Therapeutics Inc, H2 2019
Table 21: Pancreatitis - Pipeline by General Regeneratives Shanghai Ltd, H2 2019
Table 22: Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2019
Table 23: Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 24: Pancreatitis - Pipeline by GNT Pharma Co Ltd, H2 2019
Table 25: Pancreatitis - Pipeline by Johnson & Johnson, H2 2019
Table 26: Pancreatitis - Pipeline by LipimetiX Development Inc, H2 2019
Table 27: Pancreatitis - Pipeline by Mallinckrodt Plc, H2 2019
Table 28: Pancreatitis - Pipeline by Novartis AG, H2 2019
Table 29: Pancreatitis - Pipeline by PNB Vesper Life Science Pvt Ltd, H2 2019
Table 30: Pancreatitis - Pipeline by SCM lifescience Co Ltd, H2 2019
Table 31: Pancreatitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2019
Table 32: Pancreatitis - Pipeline by SN BioScience, H2 2019
Table 33: Pancreatitis - Pipeline by Sun BioPharma Inc, H2 2019
Table 34: Pancreatitis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Table 35: Pancreatitis - Dormant Projects, H2 2019
Table 36: Pancreatitis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 37: Pancreatitis - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Pancreatitis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Angion Biomedica Corp
  • Bessor Pharma LLC
  • Bharat Serums And Vaccines Ltd
  • BioNTech SE
  • CalciMedica Inc
  • Centeer BioTherapeutics Ltd Co
  • Cypralis Ltd
  • D&D Pharmatech Co Ltd
  • DiaMedica Therapeutics Inc
  • General Regeneratives Shanghai Ltd
  • Generon (Shanghai) Corp Ltd
  • GlaxoSmithKline Plc
  • GNT Pharma Co Ltd
  • Johnson & Johnson
  • LipimetiX Development Inc
  • Mallinckrodt Plc
  • Novartis AG
  • PNB Vesper Life Science Pvt Ltd
  • SCM lifescience Co Ltd
  • Shenzhen HighTide Biopharmaceutical Ltd
  • SN BioScience
  • Sun BioPharma Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll